Editorial
THINKING MORE CAREFULLY ABOUT RESPIRATORY INFECTIONS
UACS is prominent as a likely cause of all types of cough, along with Asthma, and gastro-oesophageal reflux disease, alone or in combination for patients who are not smokers or taking ACE inhibitors. Non-asthmatic eosinophilic bronchitis is a newly recognised cause, and there is a long list of rarer causes. Up to 25% of patients still have cough 14 days after commencement of the upper respiratory syndrome. Subacute cough is likely due to post-infectious cough of this type, but may be caused by pertussis. Unlike usual approaches in the American specialist literature, this group recommends initial empiric treatment for these conditions: as GPs have been doing all along. Also, unlike many guidelines that focus on one disease, they recommend, “due to the possibility of multiple causes, maintain all partially effective treatment.”
Even for gastro-oesophageal reflux, these guidelines recommend that because diagnostic tests are inadequate, observing the clinical response to empiric treatment with PPI anti-acid therapy is usually the best strategy. Response may be slow, and may also require pro-kinetic treatment for three months before it is appropriate to undertake further investigation.
This group found very limited data on many common treatments. They cite only one study of antihistamine-/decongestant (brompheniramine/pseudoephedrine) that reduced clinical symptoms and cough in upper respiratory infections, whereas terfenadine and loratidine do not. Naproxen reduced cough and other symptoms, suggesting that inflammatory responses are an important part of the cause of cough. In children, the few studies available did not demonstrate value of antihistamines so they are not recommended. Nor are decongestants and the popular combination medications.
There is limited evidence for narcotics as cough suppressants for cough caused by infections, so this group does not recommend them for symptom reduction in acute infections, only for short-term symptom reduction in chronic bronchitis. Mucolytic and mucokinetic agents have “no consistent favourable effects” so are not recommended. Even for suppressing cough due to lung cancer, narcotics are not proven, though recommended. Levodropropizine and moguisteine are two newer drugs that are peripherally active against cough from chronic causes, but not acute infections, but they are not widely used, or even available in many countries.
These reviews leave us with rather a limited set of recommendations, and the first response may be despair. However, absence of evidence is not evidence that drugs do not work. Not only that: while drugs may not appear to work well on a group of people because many do not respond, they may still work well for individuals.
So what should we do in practice? Rather than arbitrary shotgun compound mixtures, whose effects and side effects are impossible to unravel, I now recommend that patients buy single-component medications: an antihistamine, pseudoephedrine, dextromethorphan syrup, and an NSAID or paracetamol, so that each patient can test the effect of each, and adjust their doses independently. This is necessary both for pharmaco-dynamic differences between patients, and change during the progress of the disease, that often starts with a runny nose, moves on to fever and headache, with blocked nose, then sore throat. As the nose begins to clear, the cough may become severe, and gradually subside after many more days, when all other symptoms are gone. Each stage needs a different symptom management approach, and patients can learn to do this for themselves.
In my clinical practice it appears that the effective dose for pseudoephedrine for symptom relief of the common cold is widely variable: some patients may find 30mg twice a day enough, others may take the standard dose, and some may take twice that to get the effect they need. Consequently we must advise patients to find their own effective dose that does not give side effects. Older antihistamines with their cholinergic action may be particularly helpful at night, when their sedative side effects are also beneficial. It may be that most patients who find them useful have undiagnosed allergic disease, causing UACS, and such people may comprise as many as 20% of the population
This definition of the current state of knowledge may act as a wakeup call. These conditions are seen by family physicians, and we should be doing the studies, either in single practices, or more likely in research groups, producing real data from our own front line. If family medicine does not do it, we will continue to be defined by other specialist’s data, point of view, and inappropriate recommendations.
REFERENCES
- Teng CL, Syed Aljunid SM, Cheah M, Leong KC, Kwa SK Morbidity and process of care in urban Malaysian General Practice: the impact of payment system. Med J Malaysia. 2003 Aug;58(3):365-74 [PubMed]
- No author. Combination Analgesics. Bandolier Extra December 2005 www.ebandolier.com. (accessed on 20 March 2006) [Link]
- Schroeder K, Fahey T. Over the counter medications for acute cough in children and adults in ambulatory settings. The Cochrane Database of Systematic Reviews 2004 Issue 4. Art No.: CD001831.pub2. [PubMed] [Link]
- Diagnosis and Management of Cough: ACCP Evidence-based Clinical Practice guidelines. Chest. 2006 Jan;129:Supplement 1. http://www.chestjournal.org/content/vol129/1_suppl/ (accessed on 9 March 2006) [Link]
<< Page 1 | 2 >>